Funding

Sift Biosciences

United States · Biotech · AI · Enterprise software

Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases

Visit siftbio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Pre-Seed$3.7MEisai Innovation — Role not disclosedFreeflow Ventures — Role not disclosedLifespan Vision Ventures — Role not disclosedSBI US Gateway Fund — Role not disclosedValuence Ventures — Role not disclosed

Investors

Eisai InnovationPre-SeedFreeflow VenturesPre-SeedLifespan Vision VenturesPre-SeedSBI US Gateway FundPre-SeedValuence VenturesPre-Seed

Coverage

Feb 18, 2026Sift Biosciences · Pre-Seed

Similar companies

Fairy DevicesTokyo company developing wearable devices and remote-assistance software for industrial field workers.Undisclosed · JICN equity investment
Guoke Brain-ComputerBeijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.Undisclosed · Seed
Knowledge WorkTokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.¥4.8B · Series C debt second close
Sourcessiftbio.com ↗